nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.02.2016 | Consensus Statement

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly

verfasst von: M. G. Baroni, F. Giorgino, V. Pezzino, C. Scaroni, A. Avogaro

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic decisions for the treatment of hyperglycemia in patients with growth hormone and corticosteroid excess. Both the SID and SIE appointed members to represent each society and to collaborate in Guidelines writing. Members were chosen for their specific knowledge in the field. Each member agreed to produce—and regularly update—conflicts of interest. The authors of these guidelines prepared their contributions following the recommendations for the development of Guidelines, using the standard classes of recommendation shown below. All members of the writing committee provided editing and systematic review of each part of the manuscript, and discussed the grading of evidence. Consensus was guided by a systematic review of all available trials and by interactive discussions.

Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N (2000) Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549–555CrossRef

Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a meta analysis. J Clin Endocrinol Metab 93:61–67PubMedCrossRef

Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M, Correra M, Ghiggi MR, Ferretti E, Angeli A, Sicolo N, Trischitta V, Liuzzi A, Cassone R, Tamburrano G (2001) Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 54:189–195CrossRef

Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674PubMedCrossRef

Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199PubMed

Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152PubMedCrossRef

Biering H, Knappe G, Gerl H, Lochs H (2000) Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 27:27–31PubMedCrossRef

Kreze A, Kreze-Spirova E, Mikulecky M (2001) Risk factors for glucose intolerance in active acromegaly. Braz J of Med Biol Res 34:1429–1433CrossRef

Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-Chazot F, Brue T, French Acromegaly Registry (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164:877–884PubMedCrossRef

10.

Nabarro JDN (1987) Acromegaly. Clin Endocrinol (Oxf) 26:481–512CrossRef

11.

Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632–642PubMedCrossRef

12.

Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479–484CrossRef

13.

Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976–981PubMedCrossRef

14.

Clore JN, Thurby-Hay L (2009) Glucocorticoid-induced hyperglycemia. Endocr Pract 15:469–474PubMedCrossRef

15.

Mazziotti G, Gazzaruso C, Giustina A (2011) Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 22:499–506PubMedCrossRef

16.

Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R, Papadopoulos NM, Chrousos GP (1996) Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J 43:645–655PubMedCrossRef

17.

Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G (2004) High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 61:768–777CrossRef

18.

Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Koya D, Haneda M, Kashiwagi A, Yamauchi A (2007) Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 105:c54–c57PubMedCrossRef

19.

Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M (2004) Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 24:508–514PubMedCrossRef

20.

Giordano C, Guarnotta V, Pivonello R, Amato MC, Simeoli C, Ciresi A, Cozzolino A, Colao A (2014) Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur J Endocrinol 170:311–319PubMedCrossRef

21.

Rizza RA, Mandarino LJ, Gerich JE, Effects of growth hormone on insulin action in man (1982) Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663–669PubMedCrossRef

22.

Moller N, Schmitz O, Jorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J (1992) Basal and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 74:1012–1019PubMed

23.

Moller N, Butler PC, Antsiferov MA, Alberti KG (1989) Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia 32:105–110PubMedCrossRef

24.

Nielsen S, Moller N, Christiansen JS, Jorgensen JO (2001) Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 50:2301–2308PubMedCrossRef

25.

Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L (2003) Growth hormone replacement therapy induces insulin resistance by activating the glucose–fatty acid cycle. J Clin Endocrinol Metab 88:1455–1463PubMedCrossRef

26.

Dominici FP, Cifone D, Bartke A, Turyn D (1999) Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone transgenic mice. J Endocrinol 161:383–392PubMedCrossRef

27.

Giorgino F, Pedrini MT, Matera L, Smith RJ (1997) Specific increase in p85α expression in response to dexamethasone is associated with inhibition of Insulin-like Growth Factor-I stimulated phosphatidylinosito I 3-kinase activity in cultured muscle cells. J Biol Chem 272:7455–7463PubMedCrossRef

28.

Barbour LA, Rahman SM, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, McCurdy CE, Yakar S, LeRoith D, Kahn CR, Cantley LC, Friedman JE, Draznin B (2005) Increased p85α is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 280:37489–37494PubMedCrossRef

29.

Del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, Kopchick JJ, Friedman JE, Draznin B, Thorner MO (2007) Growth hormone regulation of p85α expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 56:1638–1646PubMedCrossRef

30.

Moller N, Jorgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30:152–177PubMedCrossRef

31.

van Raalte DH, Ouwens DM, Diamant M (2009) Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39:81–93PubMedCrossRef

32.

McMahon M, Gerich J, Rizza R (1988) Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 4:17–30PubMedCrossRef

33.

Kraus-Friedman N (1984) Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 64:170–259

34.

Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L (2000) Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr 19:29–34PubMedCrossRef

35.

Giorgino F, Almahfouz A, Goodyear LJ, Smith RJ (1993) Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest 91:2020–2030PubMedPubMedCentralCrossRef

36.

Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, Lombardi G, Colao A (2010) Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 92(Suppl 1):77–81PubMedCrossRef

37.

Rondinone CM (2006) Adipocyte-derived hormones, cytokines, and mediators. Endocrine 29:81–90PubMedCrossRef

38.

Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556PubMedCrossRef

39.

Gremlich S, Roduit R, Thorens B (1997) Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem 272:3216–3222PubMedCrossRef

40.

Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, Dall’Omo AM, Imbimbo B (1983) An in vivo and in vitro study of the mechanism of prednisone- induced insulin resistance in healthy subjects. J Clin Invest 72:1814–1820PubMedPubMedCentralCrossRef

41.

Wajngot A, Giacca A, Grill V, Vranic M, Efendic S (1992) The diabetogenic effects of glucocorticoids are more pro- nounced in low- than in high-insulin responders. Proc Natl Acad Sci USA 89:6035–6039PubMedPubMedCentralCrossRef

42.

Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517PubMedCrossRef

43.

Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, HO K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148PubMedCrossRef

44.

Katznelson L, Atkinson JLD, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK (2011) Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly: 2011 Update. Endocr Pract 17(Suppl 4):1–44PubMedCrossRef

45.

Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, First-line Ghigo E (2006) Therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly Primary Medical Treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 29:1017–1020PubMedCrossRef

46.

Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308–3314PubMedCrossRef

47.

Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518–523PubMedCrossRef

48.

Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(4405):4410

49.

Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results. J Clin Endocrinol Metab 88:3090–3098PubMedCrossRef

50.

Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G (2006) First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 64:342–351CrossRef

51.

Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177PubMedCrossRef

52.

van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754–1759PubMedCrossRef

53.

Wasada T, Aoki K, Sato A, Katsumori K, Muto K, Tomonaga O, Yokoyama H, Iwasaki N, Babazono T, Takahashi C, Iwamoto Y, Omori Y, Hizuka N (1997) Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. Endocr J 44:617–620PubMedCrossRef

54.

Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K, Yamada S, Takeuchi Y (2011) Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic β-cell function is preserved. Eur J Endocrinol 164:467–473PubMedCrossRef

55.

Battezzati A, Benedini S, Fattorini A, Losa M, Mortini P, Bertoli S, Lanzi R, Testolin G, Biolo G, Luzi L (2003) Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab 284:E823–E829PubMedCrossRef

56.

Mori K, Iwasaki Y, Kawasaki-Ogita Y, Honjo S, Hamamoto Y, Tatsuoka H, Fujimoto K, Ikeda H, Wada Y, Takahashi Y, Takahashi J, Koshiyama H (2013) Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J Endocrinol Invest 36:853–859PubMed

57.

Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94:528–537PubMedCrossRef

58.

Tzanela M, Vassiliadi DA, Gavalas N, Szabo A, Margelou E, Valatsou A, Vassilopoulos C (2011) Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf) 75:96–102CrossRef

59.

Giordano C, Ciresi A, Amato MC, Pivonello R, Auriemma RS, Grasso LF, Galluzzo A, Colao A (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15:539–551PubMedCrossRef

60.

Stelmachowska-Banaś M, Zieliński G, Zdunowski P, Podgórski J, Zgliczyński W (2011) The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol Neurochir Pol 45:328–334PubMed

61.

Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J (2000) Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779–3785PubMedCrossRef

62.

Jezková J, Marek J, Hána V, Krsek M, Weiss V, Vladyka V, Lisák R, Vymazal J, Pecen L (2006) Gamma knife radiosurgery for acromegaly–long-term experience. Clin Endocrinol (Oxf) 64:588–595CrossRef

63.

Lee CC, Vance ML, Xu Z, Yen CP, Schlesinger D, Dodson B, Sheehan J (2014) Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 99:1273–1281PubMedCrossRef

64.

Fedele D, Molinari M, Meneghel A, Valerio A, Muggeo M, Tiengo A (1980) Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients. J Endocrinol Invest 3:149–153PubMedCrossRef

65.

Feek CM, Bevan JS, Taylor S, Brown NS, Baird JD (1981) The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly. Clin Endocrinol (Oxf) 15:473–478CrossRef

66.

Dolecek R, Kubis M, Sajnar J, Závada M (1982) Bromocriptine and glucose tolerance in acromegalics. Pharmatherapeutica 3:100–106PubMed

67.

Chiba T, Chihara K, Minamitani N, Goto B, Kadowaki S, Taminato T, Matsukura S, Fujita T (1982) Effect of long term bromocriptine treatment on glucose intolerance in acromegaly. Horm Metab Res 14:57–61PubMedCrossRef

68.

Rau H, Althoff PH, Schmidt K, Badenhoop K, Usadel KH (1993) Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion. Clin Investig 71:372–378PubMedCrossRef

69.

Roemmler J, Steffin B, Gutt B, Schneider HJ, Sievers C, Bidlingmaier M, Schopohl J (2010) The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm IGF Res 20:338–344PubMedCrossRef

70.

Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ (2012) Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 97:1187–1193PubMedCrossRef

71.

Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ (2002) A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87:1797–1804PubMedCrossRef

72.

Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 103:458–465PubMedCrossRef

73.

McKnight JA, McCance DR, Crothers JG, Atkinson AB (1989) Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. Br Med J 299:604–605CrossRef

74.

James RA, Møller N, Chatterjee S, White M, Kendall-Taylor P (1991) Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabet Med 8:517–523PubMedCrossRef

75.

Koop BL, Harris AG, Ezzat S (1994) Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 130:581–586PubMedCrossRef

76.

Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M (1995) Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 27:226–230PubMedCrossRef

77.

Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G (1995) Effects of treatment with octreotide in acromegalic patients–a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 133:430–439PubMedCrossRef

78.

Hizuka N (1997) Divergent effects of octreotide on glucose tolerance in patients with acromegaly. Intern Med 36:319–320PubMedCrossRef

79.

Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J (2006) Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155:73–78PubMedCrossRef

80.

Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500–1508PubMedCrossRef

81.

Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M (2002) Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 25:502–507PubMedCrossRef

82.

Ronchi C, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M (2006) Comparison between six-yeartherapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121–128PubMedCrossRef

83.

Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D’Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492–499CrossRef

84.

Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective stuidy of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397–1403PubMedCrossRef

85.

Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, Pivonello R (2009) Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 94:2907–2914PubMedCrossRef

86.

Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavò S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A (2011) Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164:341–347PubMedCrossRef

87.

Couture E, Bongard V, Maiza JC, Bennet A, Caron P (2012) Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary 15:518–525PubMedCrossRef

88.

Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, Pivonello R, Amato M, Giordano C, Mariotti S, Colao A, Baroni MG (2012) Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest 35:154–159PubMed

89.

Feelders RA, de Herder WW, Neggers SJ, van der Lely AJ, Hofland LI (2013) Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc) 49:89–103CrossRef

90.

Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791–799PubMedPubMedCentral

91.

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A, Pasireotide C2402 Study Group (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875–884PubMedCrossRef

92.

Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM, Pasireotide Acromegaly Study Group (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95:2781–2789PubMedCrossRef

93.

Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A (2014) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18:385–394PubMedCentralCrossRef

94.

Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87:1692–1699PubMedCrossRef

95.

Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ (2003) The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 59:168–174CrossRef

96.

Rose DR, Clemmons DR (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormon IGF Res 12:418–424CrossRef

97.

Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521–527PubMedCrossRef

98.

Jorgensen JO, Feldt-Rasmussen U, Fgrystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627–5631PubMedCrossRef

99.

Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75–82PubMedCrossRef

100.

De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A (2007) Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 10:227–232PubMedCrossRef

101.

Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467–477PubMedCrossRef

102.

Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684–5691PubMedCrossRef

103.

Lindberg-Larsen R, Moller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jorgensen JO (2007) The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724–1728PubMedCrossRef

104.

Higham CE, Rowles S, Russel-Jones D, Umpleby AM, Trainer PJ (2009) Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94:2459–2463PubMedCrossRef

105.

Trainer PJ, Ezzat S, D’Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71:549–557CrossRef

106.

Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F (2013) Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol 169:99–108PubMedCrossRef

107.

Madsen M, Poulsen PL, Orskov H, Moller N, Jorgensen JO (2011) Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 96:2405–2413PubMedCrossRef

108.

Kumar V, Gulatia RK, Ahuja MM (1971) A clinical and biochemical study of 12 cases of acromegaly with special reference to plasma I.R.I. and FFA on glibenclamide administration. J Assoc Phys India 19:623–677

109.

Watanabe A, Komine F, Nirei K, Tamura K, Nabe K, Aiba N, Kamoshida S, Otsuka M, Okubo H, Kanou M, Sawada S, Uchiyama T, Nakamura S, Arakawa Y (2004) A case of secondary diabetes mellitus with acromegaly improved by pioglitazone. Diabet Med 21:1049–1050PubMedCrossRef

110.

Kim DDW, Goh J, Panossian Z, Gamble G, Holdaway I, Grey A (2012) Pioglitazone in acromegaly: an open-label, prospective study. Clin Endocrinol (Oxf) 77:575–578CrossRef

111.

Arnaldi et al (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602PubMedCrossRef

112.

Arnaldi G et al (2004) Cardiovascular risk in Cushing’s syndrome. Pituitary 7:253–256PubMedCrossRef

113.

Mancini T et al (2010) Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag 21:505–516

114.

Gola M et al (2005) Growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 90:1864–1870PubMedCrossRef

115.

Filipsson H et al (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954–3961PubMedCrossRef

116.

Mazziotti G et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15–20PubMedCrossRef

117.

Zeiger MA et al (2009) American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incident alomas: executive summary of recommendations. Endocr. Pract. 15:450–453PubMedCrossRef

118.

Terzolo M et al (2007) Subclinical Cushing’s syndrome. Arq Bras Endocrinol Metabol 51:1272–1279PubMedCrossRef

119.

Colao A et al (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84:2664–2672PubMed

120.

Webb SM et al (2010) Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing’s disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab 95:630–638PubMedCrossRef

121.

Faggiano A et al (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527–2533PubMedCrossRef

122.

Giordano R, Picu A, Marinazzo E et al (2011) Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 75:354–360CrossRef

123.

Colao A, Boscaro M, Ferone D, Casanueva FF (2014) Managing Cushing’s disease: the state of the art. Endocrine 47:9–20PubMedCrossRef

124.

Nieman LK (2013) Update in the medical therapy of Cushing’s disease. Curr Opin Endocrinol Diabetes Obes 20(4):330–334. doi:10.1097/MED.0b013e3283631809 PubMedPubMedCentral

125.

Gadelha MR, Vieira Neto L (2014) Efficacy of medical treatment in Cushing’s disease: a systematic review. Clin Endocrinol 80(1):1–12. doi:10.1111/cen.12345 CrossRef

126.

Biller BM et al (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462PubMedPubMedCentralCrossRef

127.

Castinetti F et al (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol 158:91–99PubMedCrossRef

128.

Valassi E et al (2012) A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol 77:735–742CrossRef

129.

Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E, Philippon M, Morange I, Conte-Devolx B, Quinquis L, Martinie M, Vezzosi D, Le Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O, Tabarin A, Bertherat J, Brue T (2014) Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab 99(5):1623–1630PubMedCrossRef

130.

Verhelst et al (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 35(2):169–178CrossRef

131.

Yoshida et al (2012) Assessment of long-term efficacy and safety of metyrapone monotherapy in a patient with ACTH-independent macronodular adrenal hyperplasia. Endocrine 41:160–161PubMedCrossRef

132.

Omori et al (2001) Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH). Endocr J 48(6):665–669PubMedCrossRef

133.

Jeffcoate et al (1977) Metyrapone in long-term management of Cushing’s disease. Br Med J 2(6081):215–217PubMedPubMedCentralCrossRef

134.

Castinetti et al (2009) Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol 160:1003–1010PubMedCrossRef

135.

Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL (1985) Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536–540PubMedCrossRef

136.

Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D (2001) Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86:3568–3573PubMed

137.

Cassier PA, Abou-Amara-Olivieri S, Artru P, Lapalus MG, Riou JP, Lombard-Bohas C (2008) Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases. Eur J Endocrinol 158:935–938PubMedCrossRef

138.

Fleseriu et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with cushing’s syndrome. J Clin Endocrinol Metab 97(6):2039–2049PubMedCrossRef

139.

Pivonello et al (2009) The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223–230PubMedCrossRef

140.

Vilar L, Naves LA, Azevedo MF et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary 13(2):123–129PubMedCrossRef

141.

Barbot M, Albiger N, Ceccato F et al (2014) Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17(2):109–117PubMedCrossRef

142.

Pecori-Giraldi F et al (2006) Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing’s disease. Clin Endocrinol 64:219–224CrossRef

143.

Ambrosi B et al (2004) Effects of chronic administration of PPARgamma ligand rosiglitazone in Cushing’s disease. Eur J Endocrinol 151:173–178PubMedCrossRef

144.

Suri D, Weiss RE (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing’s disease. J Clin Endocrinol Metab 90:1340–1346PubMedCrossRef

145.

Pecori Giraldi F, Ambrogio AG, Andrioli M et al (2012) Potential role for retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab 97(10):3577–3583PubMedCrossRef

146.

Schonbrunn A (1982) Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 110:1147–1154PubMedCrossRef

147.

Giustina A et al (1991) Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. Diabetes Res Clin Pract 14:47–54PubMedCrossRef

148.

Colao A, Petersenn S, Newell-Price J et al (2012) Asireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924PubMedCrossRef

149.

Boscaro M, Ludlam WH, Atkinson B et al (2009) Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94(1):115–122PubMedCrossRef

150.

Ben-Shlomo A et al (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94:4342–4350PubMedCrossRef

151.

Pedroncelli AM (2010) Medical treatment of Cushing’s disease: somatostatin analogues and pasireotide. Neuroendocrinology 92:120–124PubMedCrossRef

152.

Occhi G, Regazzo D, Albiger NM et al (2014) Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing’s disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation. Endocrinology 155:3538–3549

153.

Mitra SW et al (1999) Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 140:3790–3796PubMed

154.

Petersenn S et al (2011) Pasireotide (SOM230), a novel multi-receptor targeted somatostatin analogue, is well tolerated when administered as a continuous 7 day subcutaneous infusion in healthy male volunteers. J Clin Pharmacol 52:1017–1027PubMedCrossRef

155.

Doga M et al (2006) Growth hormone deficiency in the adult. Pituitary 9:305–311PubMedCrossRef

156.

Giustina A et al (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535–559PubMedPubMedCentralCrossRef

157.

Henry et al (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446–3453PubMedCrossRef

158.

Mackenzie Feder J, Bourdeau I, Vallette S, Beauregard H, Ste-Marie LG, Lacroix A (2013) Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial. Pituitary 17:519–529CrossRef

159.

Trementino L, Cardinaletti M, Concettoni C, Marcelli G, Boscaro M, Arnaldi G (2014) Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary 18:359–365CrossRef

160.

Feelders RA et al (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med 362:1846–1848PubMedCrossRef

161.

Boscaro et al (2014) Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study. Pituitary 17:320–326PubMedPubMedCentralCrossRef

162.

Taghavi SM, Fatemi SS, Rokni H (2012) Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. Med J Malaysia 67(4):390–392PubMed

163.

Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J (2012) Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab 14(4):335–340PubMedPubMedCentralCrossRef

164.

Gurwitz JH et al (1994) Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 154:97–101PubMedCrossRef

165.

Henriksen JE, Alford F, Ward GM, Beck-Nielsen H (1997) Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 40:1439–1448PubMedCrossRef

166.

Darmon P et al (2006) Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. Am J Physiol 291:E995–E1002CrossRef

167.

Donihi AC et al (2006) Prevalence and predictors of corticosteroid related hyperglycemia in hospitalized patients. Endocr Pract 12:358–362PubMedCrossRef

168.

Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R (2014) Glucocorticoid-induced hyperglycemia. J. Diabetes 6(1):9–20CrossRef

169.

Mancini T et al (2009) Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45:784–788PubMedCrossRef

170.

Mazziotti G et al (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884PubMedCrossRef

171.

Home PD et al (2007) Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 357:28–38PubMedCrossRef

172.

Van Raalte DH et al (2011) Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34:412–417PubMedPubMedCentralCrossRef

173.

Matsuo et al (2013) Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy. Intern Med 52:89–95PubMedCrossRef

174.

Dhital SM, Shenkery Y, Meredith M et al (2012) A retrospective study comparing neutral protamine hagedorm insulin with glargine as basal therapy in prednisone associated diabetes mellitus in hospitalized patients. Endocr Pract 18:712–719PubMedPubMedCentralCrossRef

175.

Lansang MC, Hustak LK (2011) Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med 78(11):748–756PubMedCrossRef

176.

Newell-Price (2010) Management of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 92(Suppl 1):82–85PubMed

177.

Ritzel RA, Kleine N, Holst JJ, Willms B, Schmiegel W, Nauck MA (2007) Preserved GLP-1 effects in a diabetic patient with Cushing’s disease. Exp Clin Endocrinol Diabetes 115:146–150PubMedCrossRef

178.

Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180–186PubMedPubMedCentralCrossRef

179.

Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S, Vergès B (2013) Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab 39(1):34–41PubMedCrossRef

180.

Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379PubMedPubMedCentralCrossRef

Titel: Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly
verfasst von: M. G. Baroni
F. Giorgino
V. Pezzino
C. Scaroni
A. Avogaro
Publikationsdatum: 01.02.2016
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 2/2016
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0404-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Antonello da Messina: Virgin Annunciate

A non-invasive prevention program model for the assessment of osteoporosis in the early postmenopausal period: a pilot study on FRAX® and QUS tools advantages

Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis

Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine

Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model